Wall Street is positive on Nektar Therapeutics (NKTR). On average, analysts give Nektar Therapeutics a Buy rating. The average price target is $21.444, which means analysts expect the stock to increase by 47.79% over the next twelve months. That average ranking earns Nektar Therapeutics an Analyst Rating of 28, which is better than 28% of stocks based on data compiled by InvestorsObserver.
Wall Street analysts are rating NKTR a Buy today. Find out what this means to you and get the rest of the rankings on NKTR!